Videos

Younossi explains the importance of patient-reported outcomes and assessing HRQoL, breaking down findings from an analysis of the MAESTRO-NAFLD trial of resmetirom.

Kremer describes recent advancements in the PBC treatment landscape and reviews findings from abstracts on elafibranor presented at AASLD The Liver Meeting 2025.

McGill emphasizes new exciting data shared at ACR 2025.

ALTUS findings presented at AASLD show mt-HBT detects early-stage HCC with >66% higher sensitivity than ultrasound, addressing gaps in liver cancer surveillance.

In a phase 3 NATRON trial presented at ACAAI 2025, Ogbogu discussed how benralizumab reduced flare in patients with hypereosinophilic syndrome.

In this segment of his SDPA Fall interview, Nguyen highlighted his second talk ‘Patterns in Red and Purple: Decoding Vasculitis in the Skin.’

AASLD-presented data show HCCs persist after weight or diabetes control, with a new target of fibrotic immune phenotype to prevent MASH-related complications.

At ACAAI 2025, Golden discussed how mild local reactions and expected systemic effects support the sublingual film’s strong safety profile in children.

McLaughlin discussed the previous ZENITH, PULSAR, and STELLAR trials, and how this pooled cohort analysis emphasizes sotatercept’s impressive efficacy.

Children achieved therapeutic epinephrine levels within 2 minutes on AQST-109 (Anaphylm), showing an early cardiovascular response similar to adults.

Data presented at AASLD 2025 hepatitis delta patients experience significant physical and emotional challenges, emphasizing the need for holistic care approaches and screening beyond risk-based recommendations.

At ACAAI 2025, Gross outlined new food allergy ICD-10 codes, clarified documentation rules, and shared tips to help allergists prevent claim denials.

In this segment of his interview, Abbas highlights when to refer a patient for systemic macrocytosis to a hematology or mast cell disease specialist.

HCPLive spoke with Al Ali at ACAAI 2025 about a study comparing the safety of protocols for milk and peanut allergens.

Katzenstein reviews noninvasive tests used for MASH and explains her research on the ELF test’s real-world potential for predicting liver stiffness.

This interview was on-site at SDPA, featuring a discussion of the tools needed to identify systemic macrocytosis.

Hirschfield describes the burden of pruritus in PBC and reviews late-breaking ASSURE data on seladelpar’s long-term impact on itch presented at AASLD The Liver Meeting.

Branch explains the evolving understanding of the role genetic variants play in driving hepatic steatosis and associated cardiovascular risk or protection.

This segment of Maloney’s interview at the SDPA Fall Conference discussed off-label uses of JAK inhibitors and other treatment news in dermatology.

Phase 3 LIBERTY AIMS data reveal significant reductions in nasal polyps, surgery, and steroid use in patients with AFRS, a challenging CRSwNP subtype.

Maloney speaks in this interview at the SDPA Fall Conference about off-label uses of JAK inhibitors in dermatology.

Dupilumab maintained histologic and endoscopic improvements across all pediatric age groups with EoE, according to Joshua Wechsler, MD.

Dale Lee, MD, told HCPLive that regular monitoring and potential psychosocial support are important to help children with celiac disease maintain a gluten-free diet.

At ACAAI 2025, Shaker dispels epinephrine myths, emphasizing that it is safe, effective, and underused in anaphylaxis care.

At ACAAI 2025, Shaker highlighted evolving therapies and real-world barriers that continue to limit optimal anaphylaxis management.

The SDPA president, Sarah Vicari, spoke at the 2025 SDPA Fall Conference about the conference and its significance.

At ACAAI 2025, Durban breaks down natural allergy treatments and separates myths from evidence.